Which has higher earnings & valuation, GNS or OXB?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.21 £7.87M £71.00 31.49 Oxford Biomedica £168.74M 4.48 -£143.51M -£26.92 N/A

Is GNS or OXB more profitable?

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Genus 7.07% 9.70% 3.31% Oxford Biomedica -17.85% -48.56% -12.67%

Does the media prefer OXB or ONT?

In the previous week, Oxford Biomedica had 2 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 3 mentions for Oxford Biomedica and 1 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 0.44 beat Oxford Biomedica's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Nanopore Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend OXB or ERGO?

Oxford Biomedica presently has a consensus target price of GBX 604.32, suggesting a potential downside of 3.31%. Given Ergomed's higher possible upside, analysts plainly believe Ergomed is more favorable than Oxford Biomedica. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is OXB or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Oxford Biomedica -17.85% -48.56% -12.67% Ergomed 9.87% 18.08% 10.16%

Do analysts rate OXB or SLN?

Oxford Biomedica presently has a consensus target price of GBX 604.32, suggesting a potential downside of 3.31%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Oxford Biomedica. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Oxford Biomedica (OXB) Competitors

GBX 625 -5.00 (-0.79%)

As of 12:21 PM Eastern

Compare

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

Should you buy Oxford Biomedica stock or one of its competitors? MarketBeat compares Oxford Biomedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Biomedica include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Genus?

Genus (LON:GNS) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.21	£7.87M	£71.00	31.49
Oxford Biomedica	£168.74M	4.48	-£143.51M	-£26.92	N/A

52.9% of Genus shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 0.7% of Genus shares are owned by company insiders. Comparatively, 43.3% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genus currently has a consensus price target of GBX 3,216.67, suggesting a potential upside of 43.86%. Oxford Biomedica has a consensus price target of GBX 604.32, suggesting a potential downside of 3.31%. Given Genus' stronger consensus rating and higher possible upside, research analysts clearly believe Genus is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Oxford Biomedica had 3 more articles in the media than Genus. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for Genus. Genus' average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
Genus	Neutral
Oxford Biomedica	Neutral

Genus has a beta of 0.896, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.096, suggesting that its stock price is 10% more volatile than the broader market.

Summary

Genus beats Oxford Biomedica on 10 of the 15 factors compared between the two stocks.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 19.6% of Oxford Nanopore Technologies shares are held by institutional investors. 43.3% of Oxford Biomedica shares are held by insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Oxford Biomedica had 2 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 3 mentions for Oxford Biomedica and 1 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 0.44 beat Oxford Biomedica's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Nanopore Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oxford Biomedica has a beta of 1.096, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.869, indicating that its stock price is 13% less volatile than the broader market.

Oxford Biomedica presently has a consensus target price of GBX 604.32, suggesting a potential downside of 3.31%. Oxford Nanopore Technologies has a consensus target price of GBX 218.60, suggesting a potential upside of 67.00%. Given Oxford Nanopore Technologies' higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.48	-£143.51M	-£26.92	N/A
Oxford Nanopore Technologies	£223.90M	5.69	-£175.21M	-£15.10	N/A

Summary

Oxford Biomedica beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Ergomed?

Oxford Biomedica (LON:OXB) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Oxford Biomedica presently has a consensus target price of GBX 604.32, suggesting a potential downside of 3.31%. Given Ergomed's higher possible upside, analysts plainly believe Ergomed is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ergomed has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.48	-£143.51M	-£26.92	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Ergomed	9.87%	18.08%	10.16%

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 43.3% of Oxford Biomedica shares are held by company insiders. Comparatively, 18.2% of Ergomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oxford Biomedica has a beta of 1.096, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

In the previous week, Oxford Biomedica had 3 more articles in the media than Ergomed. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for Ergomed. Oxford Biomedica's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Ergomed	Neutral

Summary

Ergomed beats Oxford Biomedica on 8 of the 14 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Oxford Biomedica (LON:OXB) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Silence Therapeutics	N/A	N/A	N/A

Oxford Biomedica presently has a consensus target price of GBX 604.32, suggesting a potential downside of 3.31%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

32.4% of Oxford Biomedica shares are held by institutional investors. 43.3% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oxford Biomedica had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for Silence Therapeutics. Oxford Biomedica's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Silence Therapeutics	Neutral

Silence Therapeutics has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.48	-£143.51M	-£26.92	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

Summary

Oxford Biomedica beats Silence Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Oxford Biomedica compare to Avacta Group?

Avacta Group (LON:AVCT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Avacta Group has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.096, suggesting that its share price is 10% more volatile than the broader market.

In the previous week, Oxford Biomedica had 3 more articles in the media than Avacta Group. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
Avacta Group	Neutral
Oxford Biomedica	Neutral

2.9% of Avacta Group shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 49.1% of Avacta Group shares are held by company insiders. Comparatively, 43.3% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Avacta Group has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,796.87	-£30.08M	-£9.66	N/A
Oxford Biomedica	£168.74M	4.48	-£143.51M	-£26.92	N/A

Avacta Group currently has a consensus target price of GBX 99, suggesting a potential upside of 42.56%. Oxford Biomedica has a consensus target price of GBX 604.32, suggesting a potential downside of 3.31%. Given Avacta Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Avacta Group beats Oxford Biomedica on 8 of the 15 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OXB vs. The Competition

Export

Metric	Oxford Biomedica	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£756.31M	£444.28M	£6.49B	£2.74B
Dividend Yield	4.57%	3.86%	2.67%	6.16%
P/E Ratio	-23.22	3.15	20.24	366.44
Price / Sales	4.48	6,458.64	507.57	87,084.52
Price / Cash	3.01	13.13	26.99	27.85
Price / Book	9.23	83.79	10.28	7.61
Net Income	-£143.51M	-£96.07M	£3.57B	£5.89B
7 Day Performance	1.46%	-2.35%	-1.43%	-0.95%
1 Month Performance	-3.70%	0.92%	3.27%	1.56%
1 Year Performance	81.95%	64.13%	23.37%	72.41%

Oxford Biomedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OXB Oxford Biomedica	0.8367 of 5 stars	GBX 625 -0.8%	GBX 604.32 -3.3%	+83.4%	£756.31M	£168.74M	N/A	891	Gap Down
GNS Genus	2.6117 of 5 stars	GBX 2,266 +1.3%	GBX 3,216.67 +42.0%	+14.3%	£1.50B	£672M	31.92	480	Gap Up
ONT Oxford Nanopore Technologies	2.6186 of 5 stars	GBX 133.40 -0.8%	GBX 218.60 +63.9%	+11.3%	£1.30B	£223.90M	N/A	1,281
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Biomedica (OXB) Competitors

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

How does Oxford Biomedica compare to Genus?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Summary

How does Oxford Biomedica compare to Ergomed?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Summary

How does Oxford Biomedica compare to Avacta Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Biomedica (OXB) Competitors

OXB vs. GNS, ONT, ERGO, SLN, and AVCT

How does Oxford Biomedica compare to Genus?

Is GNS or OXB more profitable?

Which has higher earnings & valuation, GNS or OXB?

Do institutionals and insiders hold more shares of GNS or OXB?

Do analysts rate GNS or OXB?

Does the media favor GNS or OXB?

Which has more volatility & risk, GNS or OXB?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Do institutionals & insiders hold more shares of OXB or ONT?

Does the media prefer OXB or ONT?

Which has more risk and volatility, OXB or ONT?

Do analysts rate OXB or ONT?

Is OXB or ONT more profitable?

Which has better earnings & valuation, OXB or ONT?

Summary

How does Oxford Biomedica compare to Ergomed?

Do analysts recommend OXB or ERGO?

Which has higher earnings and valuation, OXB or ERGO?

Is OXB or ERGO more profitable?

Do insiders and institutionals believe in OXB or ERGO?

Which has more volatility and risk, OXB or ERGO?

Does the media prefer OXB or ERGO?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Is OXB or SLN more profitable?

Do analysts rate OXB or SLN?

Do institutionals and insiders believe in OXB or SLN?

Does the media favor OXB or SLN?

Which has preferable earnings and valuation, OXB or SLN?

Summary

How does Oxford Biomedica compare to Avacta Group?

Is AVCT or OXB more profitable?

Which has more volatility and risk, AVCT or OXB?

Does the media favor AVCT or OXB?

Do institutionals & insiders hold more shares of AVCT or OXB?

Which has higher earnings & valuation, AVCT or OXB?

Do analysts prefer AVCT or OXB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools